Aprile Paola, Letourneur Didier, Simon-Yarza Teresa
LVTS INSERM U1148, X. Bichat Hospital, Université de Paris, Université Sorbonne Paris Nord, Paris, F-75018, France.
Adv Healthc Mater. 2020 Oct;9(19):e2000707. doi: 10.1002/adhm.202000707. Epub 2020 Aug 31.
Bone resorption can negatively influence the osseointegration of dental implants. Barrier membranes for guided bone regeneration (GBR) are used to exclude nonosteogenic tissues from influencing the bone healing process. In addition to the existing barrier membranes available on the market, a growing variety of membranes for GBR with tailorable physicochemical properties are under preclinical evaluation. Hence, the aim of this review is to provide a comprehensive description of materials used for GBR and to report the main industrial and regulatory aspects allowing the commercialization of these medical devices (MDs). In particular, a summary of the main attributes defining a GBR membrane is reported along with a description of commercially available and under development membranes. Finally, strategies for the scaling-up of the manufacturing process and the regulatory framework of the main MD producers (USA, EU, Japan, China, and India) are presented. The description of the regulatory approval process of GBR membranes is representative of the typical path that medium- to high-risk MDs have to follow for an effective medical translation, which is of fundamental importance to increase the impact of biomedical research on public health.
骨吸收会对牙种植体的骨整合产生负面影响。引导骨再生(GBR)屏障膜用于排除非成骨组织对骨愈合过程的影响。除了市场上现有的屏障膜外,越来越多具有可定制物理化学性质的GBR膜正在进行临床前评估。因此,本综述的目的是全面描述用于GBR的材料,并报告使这些医疗器械(MDs)商业化的主要产业和监管方面。特别是,报告了定义GBR膜的主要属性的摘要以及对市售和正在开发的膜的描述。最后,介绍了扩大生产过程的策略以及主要MD生产商(美国、欧盟、日本、中国和印度)的监管框架。GBR膜监管批准过程的描述代表了中高风险MDs为实现有效的医学转化必须遵循的典型路径,这对于增强生物医学研究对公共卫生的影响至关重要。